A single-arm, multicenter, phase II study of panitumumab in combination with capecitabine/oxaliplatin in first line, wild-type KRAS metastatic colorectal cancer patients.

被引：0
|
作者：
Pectasides, Dimitrios G.
Karavasilis, Vasilios
Kotoula, Vassiliki
Samantas, Epaminontas
Alexopoulou, Zoi
Zagouri, Flora
Syrigos, Konstantinos N.
Koureas, Andreas
Dionysopoulos, Dimitrios
Lazaridis, Georgios
Efstratiou, Ioannis
Apessou, Dimitra
Pentheroudakis, George E.
Papaxoinis, George
Fountzilas, George
机构：
[1] Hellen Cooperat Oncol Grp HeCOG, Athens, CT, Greece
[2] Hlth Data Specialists Ltd, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e14563
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14563
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A single-arm phase II trial of gemcitabine, oxaliplatin, and panitumumab in KRAS wild-type advanced biliary tract cancer
    Noel, Marcus Smith
    Allen, Jill N.
    Abrams, Thomas Adam
    Yurgelun, Matthew
    Faris, Jason Edward
    Goyal, Lipika
    Clark, Jeffrey W.
    Blaszkowsky, Lawrence Scott
    Murphy, Janet E.
    Zheng, Hui
    Khorana, Alok A.
    Connolly, Gregory Clayton
    Hyrien, Ollivier
    Ng, Kimmie
    Borger, Darrell R.
    Iafrate, Anthony John
    Hezel, Aram F.
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [2] A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
    Garrido-Laguna, I.
    McGregor, K. A.
    Wade, M.
    Weis, J.
    Gilcrease, W.
    Burr, L.
    Soldi, R.
    Jakubowski, L.
    Davidson, C.
    Morrell, G.
    Olpin, J. D.
    Boucher, K.
    Jones, D.
    Sharma, S.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1257 - 1264
  • [3] A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
    I. Garrido-Laguna
    K. A. McGregor
    M. Wade
    J. Weis
    W. Gilcrease
    L. Burr
    R. Soldi
    L. Jakubowski
    C. Davidson
    G. Morrell
    J. D. Olpin
    K. Boucher
    D. Jones
    S. Sharma
    Investigational New Drugs, 2013, 31 : 1257 - 1264
  • [4] A single-arm trial of panitumumab in cetuximab refractory KRAS wild-type colorectal cancer.
    Wadlow, R. C.
    Hezel, A. F.
    Wolpin, B. M.
    Allen, J. N.
    Blaszkowsky, L. S.
    Kwak, E. L.
    Wang, R.
    Zhu, A. X.
    Ryan, D. P.
    Clark, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [5] Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
    A F Hezel
    M S Noel
    J N Allen
    T A Abrams
    M Yurgelun
    J E Faris
    L Goyal
    J W Clark
    L S Blaszkowsky
    J E Murphy
    H Zheng
    A A Khorana
    G C Connolly
    O Hyrien
    A Baran
    M Herr
    K Ng
    S Sheehan
    D J Harris
    E Regan
    D R Borger
    A J Iafrate
    C Fuchs
    D P Ryan
    A X Zhu
    British Journal of Cancer, 2014, 111 : 430 - 436
  • [6] Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
    Hezel, A. F.
    Noel, M. S.
    Allen, J. N.
    Abrams, T. A.
    Yurgelun, M.
    Faris, J. E.
    Goyal, L.
    Clark, J. W.
    Blaszkowsky, L. S.
    Murphy, J. E.
    Zheng, H.
    Khorana, A. A.
    Connolly, G. C.
    Hyrien, O.
    Baran, A.
    Herr, M.
    Ng, K.
    Sheehan, S.
    Harris, D. J.
    Regan, E.
    Borger, D. R.
    Iafrate, A. J.
    Fuchs, C.
    Ryan, D. P.
    Zhu, A. X.
    BRITISH JOURNAL OF CANCER, 2014, 111 (03) : 430 - 436
  • [7] Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
    Patel, Shiven B.
    Gill, David
    Garrido-Laguna, Ignacio
    ONCOTARGETS AND THERAPY, 2016, 9 : 75 - 86
  • [8] Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy
    Liu, Yue
    Xiao, Qian
    He, Jinjie
    Hu, Hanguang
    Du, Jinlin
    Zhu, Yuping
    Chen, Jiaqi
    Liu, Zhuo
    Wang, Jianping
    Sun, Lifeng
    Xu, Dong
    Li, Jun
    Liao, Xiujun
    Wang, Jianwei
    Cai, Yibo
    Cai, Cheng
    Jin, Zhekang
    Wang, Liuhong
    Yuan, Ying
    Ding, Kefeng
    BMC MEDICINE, 2022, 20 (01)
  • [9] Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy
    Yue Liu
    Qian Xiao
    Jinjie He
    Hanguang Hu
    Jinlin Du
    Yuping Zhu
    Jiaqi Chen
    Zhuo Liu
    Jianping Wang
    Lifeng Sun
    Dong Xu
    Jun Li
    Xiujun Liao
    Jianwei Wang
    Yibo Cai
    Cheng Cai
    Zhekang Jin
    Liuhong Wang
    Ying Yuan
    Kefeng Ding
    BMC Medicine, 20
  • [10] Panitumumab In Metastatic Colorectal Cancer with Wild-Type KRAS
    Weber, Juliane
    McCormack, Paul L.
    BIODRUGS, 2008, 22 (06) : 403 - 411
12345